Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acetylcysteine - Zambon

Drug Profile

Acetylcysteine - Zambon

Alternative Names: Fluimucil; Flumil; NSC 111180; Rinofluimucil

Latest Information Update: 09 Aug 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zambon Group SpA
  • Developer Elder Pharmaceuticals; Inpharzam Ricerche S.A.; Sermmitr; Zambon Company SpA
  • Class Antibronchitics; Antidotes; Expectorants; Reducing agents; Small molecules; Sulfur amino acids
  • Mechanism of Action Free radical inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary fibrosis

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease; Common cold; Poisoning
  • Discontinued HIV infections; Pulmonary fibrosis; Renal failure

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 09 Aug 2010 Discontinued - Phase-III for Pulmonary fibrosis in European Union (PO)
  • 29 Sep 2004 Data presented at the 14th Annual Congress of the European Respiratory Society (ERS-2004) have been added to the Respiratory Tract Disorders therapeutic trials section ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top